Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta-Analysis of Three Phase 2/3 Randomized Controlled Trials.

Clin Cardiol · 2026 · PMC13288374 · PMID 42334050

Europe PMC DOI

hedged sentence

0.3300

closest p · 6.6× alpha

0.3300

boldest claim

The sentences

did not reach statistical significancep = 0.33not close (p > 0.1)

The 0.5 mg dose did not reach statistical significance (− 2.7 mmHg; p = 0.33), which sets a practical floor between 0.5 and 1 mg and justifies carrying 1–2 mg forward into phase 3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.